Teonkang: Wholly-owned subsidiary receives registration certificate for Maxitentan tablets.

The Tencan announcement stated that its wholly-owned subsidiary, Shandong Huabokai Sheng Biotechnology Co., Ltd., recently received the "Drug Registration Certificate" for Macitentan tablets issued by the National Medical Products Administration. Macitentan is an endothelin receptor antagonist, originally developed by Actelion Pharmaceuticals and approved by the FDA for commercialization in 2013. In 2017, the original Macitentan drug was approved for commercialization in China for the treatment of pulmonary arterial hypertension to slow the progression of the disease.